Charles River Laboratories Signs Licensing Agreement with Luminex
News Jan 06, 2006
Charles River Laboratories International, Inc. and Luminex Corporation have announced that they have entered into a licensing agreement whereby Charles River will utilize Luminex's xMAP® technology within Charles River's Research Models and Services business segment.
The Luminex xMAP technology is designed to enable multiple assays to be performed in a single well, or multiplexed, utilizing suspended microspheres or beads. Up to 100 different simultaneous assays can be performed in a single microtiter well.
Charles River's Research Animal Diagnostic Services division will use the technology to create the Multiplexed Fluorometric ImmunoAssay (MFIA), which will be adopted as the platform for screening laboratory animal serum samples for infectious disease.
William Barbo, Charles River Laboratories Corporate Vice President, Research Model Services, said, "Charles River is pleased to join Luminex in this licensing agreement."
"The use of Luminex's xMAP technology in the form of MFIA will allow us the flexibility to further refine and expand our assays, delivering unparalleled products and services in the area of laboratory animal diagnostics."
Russell Bradley, Vice President of Business Development and Strategic Planning, Luminex Corporation, said, "We are pleased Charles River Laboratories has selected our xMAP technology as their multiplex platform of choice for the standardization of animal diagnostic assays."
"As a market leader, Charles River Laboratories joins a growing team of Luminex partners bringing the benefits of Luminex's bead based multiplexing to their customers."
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE